16 Months' Longer Survival with Addition of Pertuzumab in Advanced Breast Cancer (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Adding pertuzumab (Perjeta) to docetaxel and trastuzumab (Herceptin) as a first-line treatment was associated with …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Herceptin | Primary Care | Taxotere